Chinese clinical-stage biotech firm TransThera Biosciences has raked in about $100 million in a Series D round of financing to further the development of its pipeline products in the global market.
The Series D round was jointly led by CITIC’s alternative asset management unit CPE and China Structural Reform Fund. Hong Kong-listed financial institution China Renaissance, the exclusive financial advisor to the deal, announced the development in a WeChat post on Friday.
